Veeva
Life sciences cloud software and data platform provider.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Veeva Systems Inc.
- Entity type
- COMPANY
- Founded
- 2007
- Headquarters
- United States
- Company size
- >5,000
- Market role
- B2B SaaS Provider
- Ticker
- VEEV
- Official website
- veeva.com
What Veeva does
Veeva operates a vertical enterprise software model focused on regulated life sciences workflows. It creates value by offering a sector-specific cloud platform and adjacent applications that replace fragmented legacy systems, support compliance requirements, centralise content and operational data, and connect multiple functions across the product lifecycle. Revenue expands through module adoption, platform standardisation, multi-year enterprise contracts, and attached data products.
Category differentiation
Veeva is not a general consumer app or horizontal marketing platform. It is a sector-specific enterprise software and data provider focused on regulated life sciences workflows.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Veeva Systems Inc. is a public B2B software company that builds cloud applications and data products for the life sciences sector. Its product estate spans regulated content management, clinical operations, development, quality, safety, medical affairs, CRM, and commercial data, with a common platform architecture designed for pharmaceutical, biotech, and related regulated organisations. The company primarily generates revenue from recurring enterprise software subscriptions, with additional monetisation from data subscriptions, modular product licensing, and selective usage-based pricing for newer capabilities. Its customers are mainly large life sciences enterprises and their functional teams across R&D, regulatory, quality, medical, commercial, and clinical operations.
Company news briefing
Briefing updated:
Building on strong financial results and the integration of Rise Healthcare Tech, Veeva continues to expand its enterprise footprint with major global adoptions of its Vault CRM platform by Eli Lilly and Servier. Furthermore, the company has introduced advanced AI-driven capabilities, including the Study Builder Agent and Falcon Router, to accelerate clinical study configurations and triage processes. These product advancements and enterprise deployments reinforce the company's market momentum.
Business model & monetisation
The company mainly uses recurring enterprise SaaS subscriptions priced by product suite, user counts, and deployment scope. It also monetises proprietary data products through subscription licensing, supports tiered product packaging across CRM and platform modules, and has introduced usage-based charging for some newer AI-driven capabilities. Commercial upside comes from cross-selling additional clouds, data assets, and acquired capabilities into existing enterprise accounts.
- Enterprise software subscriptions
- Recurring SaaS contracts across platform and application suites
- Data subscriptions
- Licensed access to commercial and clinical data products
- Tiered product licensing
- Module and licence-level packaging within CRM and other suites
- Usage-based AI capabilities
- Consumption-based pricing for newer AI-driven features
Products & capabilities
No products with linked sources are available in this view.
Products & market categories
Competitors & alternatives
- Hitachi
Industrial and enterprise technology group selling software, infrastructure and services.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Servier Adopts Veeva OpenData Globally for AI
AI & Data Infrastructure · Recorded impact score: 3/5
Servier, a French pharmaceutical company, is standardizing its customer reference data across more than 80 countries with Veeva OpenData, part of Veeva Data Cloud. This initiative builds on Servier's use of Veeva Link Key People and aims to create an AI-ready data foundation by harmonizing fragmented data silos. The centralized data will help commercial and medical teams gain faster insights and improve efficiency. Liam Hanrahan, Director of Global Operations Excellence at Servier, highlighted that the centralized data will improve processes and enable a semantic layer for better engagement with key healthcare professionals. Veeva's president, Kilian Weiss, emphasized that 89% of AI initiatives fail due to data challenges, and Servier's data-first approach demonstrates industry leadership. The adoption replaces fragmented silos and ensures consistency for scaling advanced analytics and AI.
- Servier standardizes customer reference data with Veeva OpenData across more than 80 countries.
- The initiative builds on Servier's use of Veeva Link Key People.
Stop Anthropomorphizing LLMs, Treat Them as Tools
AI · Recorded impact score: 1/5
This article argues that marketers and tech professionals fundamentally misunderstand large language models (LLMs) by treating them as conscious entities. It explains that LLMs are statistical pattern engines that predict the next token based on probability, not logical reasoning. This leads to common failures like miscounting letters or clinging to incorrect answers. The author advises abandoning implicit logic by breaking tasks into single steps, providing tight constraints to reduce hallucinations, and not arguing with erroneous outputs. By reframing LLMs as tools rather than coworkers, marketing workflows can be made more effective and efficient.
- LLMs are predictive text engines based on statistical probability, not human logic.
- LLMs break text into tokens, which can obscure letter-level details and cause miscounting.
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Recorded impact score: 4/5
Veeva announces a new Study Builder Agent that can configure clinical studies in as little as one day, along with other updates including another Top 20 biopharma choosing Vault CRM and the introduction of Falcon Router for agentic triage.
10-Q Financial Filing Analysis for Veeva (2026-08-27)
financials · Recorded impact score: 4.3/5
Veeva Systems Inc. reported strong financial results for the second quarter of fiscal year 2027 ended July 31, 2026, with total revenue rising 18% year-over-year to $927.96 million. Top-line expansion was driven by a 16% increase in core subscription revenues to $766.76 million alongside a 24% rise in professional services to $161.20 million, driving GAAP operating income up to $275.02 million from $195.91 million in Q2 FY2026. Operationally, Veeva advanced its major migration of CRM customers from Salesforce to its proprietary Vault CRM platform (supported through 2029) and integrated Rise Healthcare Tech (Ostro), an AI-driven engagement platform acquired for $90 million, while deploying $246 million toward share repurchases.
- Q2 FY2027 total revenue grew 18% YoY to $927.96 million, led by $766.76 million in subscription revenue and $161.20 million in professional services, yielding a GAAP operating income of $275.02 million.
- The strategic migration from Salesforce to the proprietary Vault CRM platform continues ahead of the December 31, 2029 support deadline.
Eli Lilly Selects Veeva Vault CRM Globally
Customer Relationship Management (CRM) · Recorded impact score: 2/5
Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM for global deployment. Vault CRM, part of Veeva's Vault CRM Suite, is described as the technology foundation for “agentic commercial,” a commercial model that leverages AI to deliver medicines to patients. Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, and Veeva CEO Peter Gassner are quoted on the strategic expansion. Veeva is described as an industry cloud provider for life sciences serving more than 1,500 customers and operating as a Public Benefit Corporation. The announcement was distributed via PR Newswire and published on MarTech Series on August 11, 2026.
- Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM globally.
- Vault CRM is part of the Vault CRM Suite and is positioned as the technology foundation for the 'agentic commercial' model that leverages AI.
Explore company relationships
Questions about Veeva
What is Veeva?
Veeva is a public enterprise software company providing cloud applications and data products for life sciences organisations.
Who uses Veeva?
Its users are mainly pharmaceutical, biotech, CRO, regulatory, quality, safety, medical, clinical, and commercial teams inside large life sciences organisations.
How does Veeva make money?
Veeva earns revenue mainly from recurring SaaS subscriptions, plus data subscriptions, modular licensing, and some usage-based fees for newer capabilities.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
23 publicly documented primary sources and citations linked across the market graph.
Continue your research on Veeva
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.